Another example of an epigenetic-driven therapeutic intervention is peroxisome proliferator-activated receptor gamma (PPARγ) and/or alpha (PPARα) antagonists, which inhibit AQP3 expression in KCs, while agonists induce the differentiation of the latter, establishing them as a topical treatment for cutaneous diseases such as PsO. This evidence concerns the gene PPARG and dry eye syndrome.